Evaluation of Patient-Reported Outcomes in Tardive Dyskinesia Patients With Underlying Psychotic and Mood Disorders in the ARM-TD and AIM-TD Trials
Objective: To assess patients’ impression of treatment benefit from deutetrabenazine (DTB) for the treatment of tardive dyskinesia (TD). Background: In TD, patients’ perception of benefit…Tardive Dyskinesia by Body Region in Subjects with Schizophrenia/Schizoaffective Disorder or Mood Disorder: Findings from the KINECT 3 Study
Objective: To characterize dyskinesia distribution by body region in subjects with tardive dyskinesia (TD) enrolled in a clinical trial of valbenazine, based on baseline Abnormal…Deutetrabenazine is Associated with an Improvement in Involuntary Movements in Patients With Tardive Dyskinesia as Seen by the High Proportion of Responders to Deutetrabenazine Treatment in the AIM-TD Study
Objective: To examine response rates between patients receiving deutetrabenazine and placebo. Response levels were pre-specified from 10–90% improvement from baseline in Abnormal Involuntary Movement Scale…Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Improvements in Clinical Global Impression of Change (CGIC) with Deutetrabenazine Treatment in Tardive Dyskinesia (TD)
Objective: To determine the efficacy of deutetrabenazine in patients with TD as measured by CGIC. Background: TD is often irreversible and can affect any body…Estimation of Tardive Dyskinesia Incidence and Prevalence in the United States
Objective: To estimate the current and expected epidemiology of tardive dyskinesia (TD) in the United States (US), stratified by level of severity. Background: TD is…Effect of Deutetrabenazine by Body Region Score of the Abnormal Involuntary Movement Scale in Tardive Dyskinesia: ARM-TD and AIM-TD Studies
Objective: To assess the efficacy and safety of deutetrabenazine (DTB) in reducing the severity of the abnormal involuntary movements of tardive dyskinesia (TD) based on…Healthcare Utilization and Costs for Patients With Tardive Dyskinesia
Objective: To assess healthcare utilization and costs pre- and post-tardive dyskinesia (TD) diagnosis in a sample of patients from the commercially insured and Medicare Supplemental…KINECT 3: A randomized, double-blind, placebo-controlled phase 3 trial of valbenazine (NBI-98854) for tardive dyskinesia
Objective: To assess the efficacy, safety and tolerability of valbenazine (NBI-98854) for Tardive Dyskinesia (TD). Background: Tardive dyskinesia (TD) is a persistent and often disabling…Risk of movement disorders with antipsychotic drugs in patients with schizophrenia or depressive disorders
Objective: To compare the risk of movement disorders with antipsychotic drugs (APDs) in patients suffering from Schizophrenia or Depressive Disorders. Background: APDs are well-known causes…Propranolol therapy for tardive dyskinesia: A retrospective examination
Objective: To examine the tolerability and effectiveness of propranolol in treating tardive dyskinesia (TD). Background: TD is a disabling, often irreversible, movement disorder that results…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- Next Page »